Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: July 08, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: March 13, 2026
Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancer.
Journal: Research square
Published: February 12, 2026
EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.
Journal: The oncologist
Published: December 10, 2025
HyperHealth: a pilot study on AI-driven COVID-19 detection using hyperspectral fingertip images.
Journal: Scientific reports
Published: November 03, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2025
Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging.
Journal: Nature reviews. Urology
Published: October 14, 2025
Ominous-appearing serosal findings on PSMA imaging might belie indolent clinical course.
Journal: Nature reviews. Urology
Published: August 20, 2025
Pembrolizumab in recurrent or metastatic medullary thyroid cancer.
Journal: The oncologist
Published: August 14, 2025
Last Updated: 09/26/2026